FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Mannitol for bowel preparation: Efficacy and safety results from the SATISFACTION randomised clinical trial. PMID 39562215 · Dig Liver Dis · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension. PMID 39552477 · Br J Haematol · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Catheter-related thrombosis in adults with cancer: a secondary analysis of a prospective randomized controlled trial. PMID 39549836 · J Thromb Haemost · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Exposure-Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple-Negative Breast Cancer. PMID 39543869 · Clin Pharmacol Ther · 2025-Feb The record describes an exposure-response analysis combining data from phase I/II and phase III studies. While it contains results for PFS and OS from the phase III ASCENT trial, it is not the original primary or formal result report of that randomized trial. The analysis is a secondary pharmacometric study. Therefore, it does not meet the criterion of being an 'original formal-result report' of a single randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study. PMID 39542422 · Ann Oncol · 2025-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Psychometric evaluation of the Functional Assessment of chronic illness therapy-fatigue (FACIT-Fatigue) in adults with moderately to severely active Crohn's disease. PMID 39537976 · Qual Life Res · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies. PMID 39535306 · Eur J Haematol · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial. PMID 39532203 · Ann Oncol · 2025-Feb The study is a phase III randomized trial in oncology with a drug intervention, but the primary endpoint is organ preservation rate, a categorical outcome at a fixed time, not a time-to-event endpoint like OS, PFS, or DFS. No Kaplan-Meier curves or hazard ratios for survival or progression are reported or indicated as primary/secondary efficacy outcomes. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Ten-Year Outcome of a Randomized Trial: Cytoreduction and HIPEC with Mitomycin C Versus Oxaliplatin for Appendiceal Neoplasm with Peritoneal Dissemination. PMID 39531120 · Ann Surg Oncol · 2025-Feb The study is a randomized, prospective trial for a human malignancy with drug interventions (mitomycin C vs. oxaliplatin as part of HIPEC) and time-to-event endpoints (OS, PFS). However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata or abstract. The deterministic review flagged this as unclear. Therefore, is_eligible is set to false. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial. PMID 39528049 · Ann Oncol · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham. PMID 39497616 · CPT Pharmacometrics Syst Pharmacol · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study. PMID 39497468 · Diabetes Obes Metab · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of ZX-7101A, an inhibitor of influenza cap-dependent endonuclease, in adults with uncomplicated influenza: a randomized, double-blind, placebo-controlled phase 2/3 trial. PMID 39490410 · Clin Microbiol Infect · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study. PMID 39486424 · Lancet Respir Med · 2025-Feb 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Incentivizing Tobacco Helpline Engagement in Persistent Poverty Counties: A Randomized Trial. PMID 39477130 · Am J Prev Med · 2025-Feb The record is a randomized trial in humans but is not an oncology (cancer) study. It evaluates a smoking cessation intervention (financial incentives) in a population with elevated cancer risk, but the primary outcomes are behavioral (coaching calls, abstinence rates) and not cancer-specific time-to-event efficacy endpoints. It lacks a drug intervention for cancer treatment. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial. PMID 39477071 · Ann Oncol · 2025-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Low-dose and ultra-low-dose estradiol and dydrogesterone in postmenopause: an analysis by body mass index. PMID 39475406 · Climacteric · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Real-World Evidence of Crizanlizumab Showing Reductions in Vaso-Occlusive Crises and Opioid Usage in Sickle Cell Disease. PMID 39473076 · Eur J Haematol · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection. PMID 39472200 · Eur Urol · 2025-Feb The study is a randomized clinical trial in human oncology with time-to-event endpoints, but it does not involve a drug-containing intervention (comparing surgical techniques). The phase is not explicitly reported as Phase III/IIIb or Phase II/III in the provided metadata, and the signal indicates phase3 evidence is unclear. Therefore, it does not meet all required criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD. PMID 39467609 · Eur Respir J · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2. PMID 39447758 · J Am Acad Dermatol · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION). PMID 39446087 · J Urol · 2025-Feb The study is a randomized controlled trial, which is a key exclusion criterion. The primary endpoint is complete response at 3 months, not a time-to-event endpoint like OS, PFS, or DFS, and the paper does not present Kaplan-Meier curves or hazard ratios for a time-to-event outcome. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Improvement of platysma prominence with onabotulinumtoxinA: Safety and efficacy results from a randomized, double-blinded, placebo-controlled phase 3 trial. PMID 39442886 · J Am Acad Dermatol · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Reply: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial. PMID 39440683 · J Urol · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Misoprostol as Oral Solution or Oral Tablet for Induction of Labour (MISOBEST): A Randomised Controlled Non-Inferiority Trial. PMID 39440409 · BJOG · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomized, multicentre, open-label, superiority clinical trial. PMID 39433124 · Clin Microbiol Infect · 2025-Feb 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Thyroid hormone receptor-β analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). PMID 39428045 · J Hepatol · 2025-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial. PMID 39423930 · J Am Acad Dermatol · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The Prognostication of Surgically Resected Head and Neck Squamous Cell Carcinoma Using Pre-Therapy Neutrophil and Lymphocyte Counts. PMID 39415507 · Head Neck · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Drug-Drug Interaction Between Dihydroartemisinin-Piperaquine and Sulfadoxine-Pyrimethamine During Malaria Chemoprevention in Pregnant Women. PMID 39402742 · Clin Pharmacol Ther · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine. PMID 39400388 · Eur J Haematol · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle-Invasive Bladder Cancer vs White-Light Conventional and Second-resection: the 'CUT-less' Randomised Trial Protocol. PMID 39397266 · BJU Int · 2025-Feb 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial. PMID 39395662 · J Thorac Oncol · 2025-Feb The study is a secondary, supplementary analysis from a definitive Phase III randomized trial in lung cancer, but it lacks a drug-containing intervention. The trial is a surgical comparison (segmentectomy vs. lobectomy) without any drug therapy component. Therefore, it does not meet the criterion of having a drug-containing intervention. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. PMID 39393084 · Am J Respir Crit Care Med · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial. PMID 39389071 · Lancet Infect Dis · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial. PMID 39379238 · Eur Urol · 2025-Feb The trial is a randomized oncology study with a drug-containing adjuvant intervention. However, it lacks the required primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS), as the report explicitly states oncologic outcomes are immature and only reports treatment utilization and patient-reported outcomes. The phase is not explicitly stated as Phase III, and the design is a cluster-crossover trial focused on impact of testing, not a definitive efficacy comparison. Therefore, it does not meet the core eligibility criterion for a time-to-event endpoint in a Phase III/IIIb or definitive trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). PMID 39378386 · J Clin Oncol · 2025-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of up to 60 h of iv istaroxime in pre-cardiogenic shock patients: Design of the SEISMiC trial. PMID 39375885 · ESC Heart Fail · 2025-Feb This is a protocol for a non-oncology (cardiogenic shock) Phase II/III trial. It lacks a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR) and does not report results. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Comparative Analysis of Electrosurgical Energy and Hemostatic Sealant for Hemostasis in Laparoscopic Ovarian Cystectomy: A Randomized Controlled Phase III Study. PMID 39374647 · J Minim Invasive Gynecol · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Colchicine effect on biomarkers of cardiac remodelling and atherosclerosis in ST-elevation myocardial infarction: A randomized controlled trial. PMID 39359014 · Br J Clin Pharmacol · 2025-Feb The record is a randomized Phase III trial with a drug intervention (colchicine) and original results, but it is not an oncology study (it is a cardiology study for STEMI), and its primary endpoints are biomarkers, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Kansas City Cardiomyopathy Questionnaire in Relation to New York Heart Association Class. PMID 39349158 · J Card Fail · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Real-world outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial. PMID 39324506 · BJU Int · 2025-Feb The study reports real-world outcomes for patients screened for the BRAVO trial but does not present formal results of the randomized trial comparison. The trial phase is not specified as Phase III/IIIb or Phase II/III, and the results are not for the planned randomized intervention comparison. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase 3 Study. PMID 39300596 · Arthritis Rheumatol · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo-Controlled, Phase 3 Study. PMID 39300513 · Arthritis Rheumatol · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis. PMID 39293548 · Gastroenterology · 2025-Feb This is a phase 3 biomarker validation study for HCC detection in a diagnostic surveillance context. It is not a randomized trial and does not test a drug intervention or report time-to-event efficacy outcomes (e.g., OS, PFS). The primary endpoint is diagnostic performance (AUC, sensitivity, specificity). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Use of Water Sac Dilation in Resecting Parapharyngeal Space Benign Tumor via Transoral Approach. PMID 39289921 · Laryngoscope · 2025-Feb The record describes a randomized trial evaluating a surgical technique (water sac dilation) for a benign tumor. While oncology and human are true, and it is randomized with an original result, it lacks a drug-containing intervention and a time-to-event efficacy endpoint (OS, PFS, etc.), and the phase is not specified as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Chemoradiotherapy plus immunotherapy for locoregionally advanced nasopharyngeal carcinoma: A cost-effectiveness analysis. PMID 39246032 · Head Neck · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes. PMID 39226189 · ESC Heart Fail · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of macitentan in Fontan-palliated patients: 52-week randomized, placebo-controlled RUBATO Phase 3 trial and open-label extension. PMID 39216715 · J Thorac Cardiovasc Surg · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia. PMID 39213466 · J Clin Oncol · 2025-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |